PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.35%
Revenue growth under 50% of MRVL's 15.39%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.67%
Gross profit growth at 75-90% of MRVL's 10.75%. Bill Ackman would demand operational improvements to match competitor gains.
19.59%
EBIT growth below 50% of MRVL's 83.20%. Michael Burry would suspect deeper competitive or cost structure issues.
19.65%
Operating income growth under 50% of MRVL's 83.20%. Michael Burry would be concerned about deeper cost or sales issues.
20.94%
Net income growth under 50% of MRVL's 66.85%. Michael Burry would suspect the firm is falling well behind a key competitor.
22.22%
EPS growth under 50% of MRVL's 61.54%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
22.58%
Diluted EPS growth under 50% of MRVL's 75.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-1.03%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.10%
Reduced diluted shares while MRVL is at 0.11%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.21%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
78.45%
OCF growth at 50-75% of MRVL's 104.86%. Martin Whitman would question if the firm lags in monetizing sales effectively.
84.17%
FCF growth 50-75% of MRVL's 138.11%. Martin Whitman would see if structural disadvantages exist in generating free cash.
75.81%
10Y revenue/share CAGR under 50% of MRVL's 348.15%. Michael Burry would suspect a lasting competitive disadvantage.
43.93%
5Y revenue/share CAGR similar to MRVL's 46.43%. Walter Schloss might see both companies benefiting from the same mid-term trends.
9.01%
3Y revenue/share CAGR under 50% of MRVL's 28.21%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
139.61%
10Y OCF/share CAGR under 50% of MRVL's 470.87%. Michael Burry would worry about a persistent underperformance in cash creation.
96.33%
Positive OCF/share growth while MRVL is negative. John Neff might see a comparative advantage in operational cash viability.
31.16%
Positive 3Y OCF/share CAGR while MRVL is negative. John Neff might see a big short-term edge in operational efficiency.
139.45%
Below 50% of MRVL's 794.09%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
81.78%
5Y net income/share CAGR similar to MRVL's 80.86%. Walter Schloss might see both on parallel mid-term trajectories.
48.33%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
32.52%
Below 50% of MRVL's 117.01%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
31.35%
5Y equity/share CAGR at 50-75% of MRVL's 44.91%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
2.49%
Below 50% of MRVL's 12.75%. Michael Burry suspects a serious short-term disadvantage in building book value.
1346.20%
Dividend/share CAGR of 1346.20% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
173.68%
Dividend/share CAGR of 173.68% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
132.62%
3Y dividend/share CAGR of 132.62% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-3.27%
Firm’s AR is declining while MRVL shows 8.32%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
0.40%
Inventory shrinking or stable vs. MRVL's 13.45%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
0.51%
Asset growth well under 50% of MRVL's 2.76%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
1.09%
50-75% of MRVL's 2.09%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-0.06%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-4.87%
Our R&D shrinks while MRVL invests at 1.25%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.91%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.